Filing Details

 

CUSIP No. 29014R103

13G

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

 

(RULE 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS

THERETO FILED PURSUANT TO RULE 13d-2(b)

 (Amendment No. __)*

 

 

ELOXX PHARMACEUTICALS, INC.

 

(Name of Issuer)

 

Common Stock, Par Value $0.01 Per Share

(Title of Class of Securities)

 

29014R103

(CUSIP Number)

 

December 19, 2017

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨

Rule 13d-1(b)

 

x

Rule 13d-1(c)

 

¨

Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 29014R103

13G

 

1		NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)   Gilad Shabtai
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)  ¨ (b)  ¨
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION   Israel
NUMBER OF SHARES  BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH				5		SOLE VOTING POWER   3,263,970
				6		SHARED VOTING POWER     0
				7		SOLE DISPOSITIVE POWER   3,263,970
				8		SHARED DISPOSITIVE POWER     0
9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   3,263,970
10		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)   11.82% (issued basis)
12		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)   IN

 

 

CUSIP No. 29014R103

13G

 

Schedule 13G

 

Item 1(a).		Name of Issuer: Eloxx Pharmaceuticals, Inc. (the “Issuer”)
Item 1(b).		Address of Issuer’s Principal Executive Offices: 950 Winter Street, 4th Floor North, Waltham, MA 02451
Item 2(a).		Name of Persons Filing: Gilad Shabtai
Item 2(b).		Address of Principal Business Office or, if None, Residence: Unit 2706 Michelangelo Towers, 66 Maude Street, Sandton, South Africa
Item 2(c).		Citizenship: Israel
Item 2(d).		Title of Class of Securities: Common Stock, par value $0.01
Item 2(e).		CUSIP Number: 29014R103
Item 3.		If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

 

					Not applicable.
(a)	[		]		Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
(b)	[		]		Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)	[		]		Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d)	[		]		Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e)	[		]		An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)	[		]		An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)	[		]		A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)	[		]		A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	[		]		A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	[		]		Group, in accordance with §240.13d-1(b)(1)(ii)(J).

 

CUSIP No. 29014R103		13G

 

Item 4.

Ownership.

 

(a) Amount Beneficially Owned:

 

See the response to Item 9 on the attached cover page.

 

(b) Percent of Class:

 

See the response to Item 11 on the attached cover page.

 

(c) Number of shares as to which such person has:

 

(i) Sole power to vote or to direct the vote: See the response to Item 5 on the attached cover page.

 

(ii) Shared power to vote or to direct the vote: 0.

 

(iii) Sole power to dispose or to direct the disposition of: See the responses to Item 7 on the attached cover page.

 

(iv) Shared power to dispose or to direct the disposition of: 0.

 

Item 5.

Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

Item 7.

Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

 

Not applicable.

 

Item 8.

Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9.

Notice of Dissolution of Group.

 

Not applicable.

 

Item 10.

Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11.

 

 

CUSIP No. 29014R103

13G

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: December 29, 2017		/s/ Gregory Weaver, Attorney in Fact
		Signature of Reporting Person

 

EXHIBITS

 

1.       Limited Power of Attorney executed in favor of Gregory Weaver (previously filed).